CD19 and acute myeloid leukemia: However, we can extrapolate from the well-established role of the microenvironment in CAR T cell therapy for solid tumors (27, 28), clinical experience with CD19-CAR T cells for B-ALL, and evidence detailing the dynamics of the AML microenvironment.